Loading…
Loading…
Is it possible there were some pushouts from earlier in the year that might have come in around year-end
You talked about the $250 million cost actions. You also have the biotechnology segment, your highest margin segment, growing the fastest
it just wasn't obvious to me what might have fallen short at least versus what the Street was thinking
How do you think this is going to play out over the next few years
digging more into the guide for Life Sciences in 2025, that's where I'm getting most of the questions
Obviously, had the change in administration, and U.S. academic government funding has been a hot topic
how are you feeling about industry supplied demand dynamics entering 2026
do you see this competitive advantage as stable or expanding, weakening, entering this year
just great to get your latest thoughts on how you felt like you were tracking relative to that
any additional color you can share on trends and new authorizations, how you feel like pharma customers are feeling about getting back to work
just the organic growth decline this quarter. When you talk about some of the policy pressure, was this all academic
did you see any evidence customers could have been pausing purchasing at all? Just the idea being like if you're going to buy equipment
what inning you think this business is now in kind of in the post-COVID recovery, confidence that continues
Curious what you're hearing from customers and then just talk about the risks and opportunities there for Thermo Fisher Scientific
what does the exit rate look like in the fourth quarter? And just more broadly, just like confidence about your ability to get back to the LRP targets
what does the guide assume for PPD clinical research? And can you give us an update, just color on what you're seeing in terms of new authorizations